Jonathan Schott, MD, describes the use of structural imaging in Alzheimer’s disease and highlights the different presentations of atrophy in typical and atypical presentations. He then discusses PET imaging and CSF biomarkers in Alzheimer’s disease before examining the biomarker results from the patient case, alongside Giovanni Frisoni.
Disclosure: All panelists received honoraria from Biogen for participation in this symposium.
Disclaimer: All of the information discussed today is for informational purposes only; does not constitute medical advice; and is not intended to be a substitute for independent professional medical judgment, advice, diagnosis, or treatment.